
    
      This study consists of both single and multiple ascending doses in healthy subjects and in
      subjects with cholestatic or uremic pruritus.

      Up to 48 healthy subjects will receive a single dose of EP547 or placebo. There will be a
      screening period of up to 28 days prior to the first dose, and a follow up visit 7 days after
      dosing is completed.

      24 healthy subjects will receive multiple doses of EP547 or placebo for 7 days. There will be
      a screening period of up to 28 days prior to the first dose, and a follow up visit 7 days and
      then 14 days after dosing is completed.

      6 subjects with cholestatic disease will receive a single dose of EP547. There will be a
      screening period of up to 28 days prior to the first dose, and a follow up visit 7 days after
      dosing is completed.

      Up to 16 subjects with cholestatic pruritus will receive multiple doses of EP547 or placebo
      for 7 days. There will be a screening period of up to 28 days prior to the first dose, and a
      follow up visit 7 days and then 14 days after dosing is completed.

      6 subjects with uremic disease will receive a single dose of EP547. There will be a screening
      period of up to 28 days prior to the first dose, and a follow up visit 7 days after dosing is
      completed.

      Up to 16 subjects with uremic pruritus will receive multiple doses of EP547 or placebo for 7
      days. There will be a screening period of up to 28 days prior to the first dose, and a follow
      up visit 7 days and then 14 days after dosing is completed.
    
  